Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 9.01 · 8-K

Insight Molecular Diagnostics Inc.

IMDXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.…

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:00 PM ESTCIK 1642380Accession 0001493152-26-052323
Share

Company context

Current securities

Recent company filings

  1. 4 filingNov 20, 2026
  2. 4 filingNov 19, 2026
  3. Entry into a Material Definitive Agreement · Other EventsNov 18, 2026
  4. 424B5 filingNov 18, 2026
  5. 424B5 filingNov 16, 2026

Registered securities in this filing

Insight Molecular Diagnostics Inc. · 8-K · Filed 2026-11-16

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, no par value

Symbol
IMDX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-11-16

Dimensions: Not supplied

Accession 000149315226052323 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information Initiated enrollment into GALACTIC registry study from UCLA Medical Center Revenue from GraftAssureCore lab-developed test expected to build as GALACTIC enrollment grows Q3 2026 revenue of $559,000; operating expenses decline as FDA-submission costs wind down iMDx appoints veteran transplant sales leader to prepare for GraftAssureDx commercial launch NASHVILLE, Tenn., Nov. 16, 2026 - Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results: Fellow shareholders, Innovation and disruption in diagnostics tend to follow a well-known path: A new test starts in a specialized laboratory, becomes used more widely, and eventually becomes a broadly available kit that can be run at local laboratories. There are countless examples of familiar tests that have progressed toward simpler, more accessible test kits. In this classic story of decentralization, we believe that our …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.